Suven Life Sciences Pashamylaram facility successfully completes USFDA inspection
NEW DELHI: Drug firm Suven Life Sciences today said its Pashamylaram facility near Hyderabad has undergone successful inspection by the US health regulator.
The facility has undergone renewal inspection from February 5-18 by the United States Food and Drug Administration (USFDA), Suven Life Sciences said in a filing to BSE.
The plant is considered to be in an acceptable state of compliance with regards to current good manufacturing practices (CGMP) and the agency has issued an Establishment Inspection Report (EIR) for the facility, it added.
So far the company has filed 19 Drug Master Files (DMF's) and 5 abbreviated new drug applications (ANDA's) from this facility, Suven said.
The company's stock was trading 5.43 per cent up at Rs 191.10 on BSE in the afternoon.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd